1. Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours. Issue 9 (12th April 2020) Authors: Mahalingam, Devalingam; Patel, Manish R.; Sachdev, Jasgit C.; Hart, Lowell L.; Halama, Niels; Ramanathan, Ramesh K.; Sarantopoulos, John; Völkel, Dirk; Youssef, Ashraf; de Jong, Floris A.; Tsimberidou, Apostolia Maria Journal: British journal of clinical pharmacology Issue: Volume 86:Issue 9(2020) Page Start: 1836 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗